Summit Therapeutics Plc Stock Analysis

Summit Stock Analysis Notes

About 88.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.99. Summit Therapeutics PLC had not issued any dividends in recent years. The entity had 1:1 split on the 21st of September 2020. Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. The company was founded in 2003 and is based in Cambridge, Massachusetts. Summit Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Summit Therapeutics PLC contact Robert Duggan at 650 460 8308 or learn more at https://www.summittxinc.com.

Summit Therapeutics PLC Investment Alerts

Summit Therapeutics PLC Upcoming and Recent Events

Summit Largest EPS Surprises

View All Earnings Estimates

Summit Therapeutics Thematic Classifications

Summit Stock Institutional Investors

Note, although Summit Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Summit Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.57 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Summit Therapeutics's market, we take the total number of its shares issued and multiply it by Summit Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Summit Profitablity

Management Efficiency

Summit Therapeutics PLC has return on total asset (ROA) of (0.1279) % which means that it has lost $0.1279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.0185) %, meaning that it created substantial loss on money invested by shareholders. Summit Therapeutics' management efficiency ratios could be used to measure how well Summit Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -2.91 in 2024. Return On Capital Employed is likely to drop to -0.52 in 2024. At this time, Summit Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 110.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 11 M in 2024.

Technical Drivers

As of the 16th of April 2024, Summit Therapeutics has the Semi Deviation of 6.9, risk adjusted performance of 0.0558, and Coefficient Of Variation of 1325.3. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Summit Therapeutics PLC, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We have collected data for nineteen technical drivers for Summit Therapeutics PLC, which can be compared to its competition. Please validate Summit Therapeutics PLC standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Summit Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 3.66 per share. Given that Summit Therapeutics PLC has jensen alpha of 0.3651, we advise you to double-check Summit Therapeutics PLC's current market performance to make sure the company can sustain itself at a future point.

Summit Therapeutics PLC Price Movement Analysis

Summit Therapeutics PLC Insider Trading Activities

Summit Therapeutics Predictive Daily Indicators

Summit Therapeutics Corporate Filings

Summit Therapeutics Forecast Models

Summit Therapeutics' time-series forecasting models are one of many Summit Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Summit Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Summit Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Summit shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Summit Therapeutics. By using and applying Summit Stock analysis, traders can create a robust methodology for identifying Summit entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Summit analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Summit analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Summit Therapeutics PLC stock analysis indicators help investors evaluate how Summit Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Summit Therapeutics shares will generate the highest return on investment. By understating and applying Summit Therapeutics stock analysis, traders can identify Summit Therapeutics position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Summit Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Summit Therapeutics. If investors know Summit will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Summit Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Summit Therapeutics PLC is measured differently than its book value, which is the value of Summit that is recorded on the company's balance sheet. Investors also form their own opinion of Summit Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Summit Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Summit Therapeutics' market value can be influenced by many factors that don't directly affect Summit Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Summit Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Summit Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Summit Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.